NASDAQ:TRVI
Trevi Therapeutics Inc. Stock News
$2.57
-0.0200 (-0.772%)
At Close: May 31, 2024
Trevi Therapeutics Announces Additions to the Senior Leadership Team
04:05pm, Monday, 09'th Aug 2021
NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigation
Trevi Therapeutics to Report Q2 2021 Financial Results on August 12
04:05pm, Thursday, 05'th Aug 2021
NEW HAVEN, Conn., Aug. 5, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigation
Trevi Therapeutics to Present at 2021 BIO Digital Conference
07:30am, Wednesday, 09'th Jun 2021
NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigatio
Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q1 2021 Results - Earnings Call Transcript
09:33am, Friday, 14'th May 2021
Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q1 2021 Results - Earnings Call Transcript
Trevi Therapeutics to Report Q1 2021 Financial Results on May 13
04:05pm, Thursday, 06'th May 2021
NEW HAVEN, Conn., May 6, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigationa
Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
07:30am, Wednesday, 07'th Apr 2021
NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™
Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q4 2020 Results - Earnings Call Transcript
07:00pm, Thursday, 25'th Mar 2021
Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q4 2020 Results - Earnings Call Transcript
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
04:05pm, Thursday, 25'th Mar 2021
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021
Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25
04:05pm, Thursday, 18'th Mar 2021
Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET
Trevi Therapeutics' (TRVI) Shares March Higher, Can It Continue?
08:21am, Wednesday, 03'rd Feb 2021
As of late, it has definitely been a great time to be an investor in Trevi Therapeutics (TRVI).
Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer
07:30am, Monday, 01'st Feb 2021
Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications
Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update
04:05pm, Wednesday, 11'th Nov 2020
PRISM Trial of Haduvio ™ for Severe Pruritus in Patients with Prurigo Nodularis
Trevi Therapeutics to Present at Stifel Healthcare Conference
07:30am, Tuesday, 10'th Nov 2020
NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (
Trevi Therapeutics to Report Q3 2020 Financial Results on November 11
04:05pm, Wednesday, 04'th Nov 2020
Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET
